Turkey
Arven Pharmaceuticals, founded in 2013, is a pioneering force in the Biotechnology and Pharmaceutical industries, headquartered in Turkey. With the motto "Hücreden Bitmiş Ürüne- Biyoteknoloji", the company specializes in developing inhalation products and biologics, emphasizing products that are notoriously complex to manufacture.
A strategic initiative by the Toksoz Group, Arven has carved a niche in delivering high quality biosimilars, conforming to global regulations like WHO, ICH, FDA, and EMA. Setting a benchmark as the first Turkish company aiming to develop biosimilars for regions including the USA and EU, this underscores their strategy of "One Product Globally".
Boasting a state-of-the-art 28,000 square meter facility in Kirklareli, Turkey, Arven's core competencies include therapeutic protein production and advanced analytical studies. Intriguingly, despite its notable growth, the firm has yet to attract external investment, highlighting a unique potential for investors seeking presence in the biopharma landscape.
